<DOC>
	<DOCNO>NCT00814658</DOCNO>
	<brief_summary>The purpose study evaluate combination galantamine nimodipine patient mixed dementia cognition quality life .</brief_summary>
	<brief_title>The Use Galantamine ( Reminyl ER ) Patients With MIXed Dementia : Effects Cognition Quality Life</brief_title>
	<detailed_description>A double-blind ( neither patient physician know name study drug ) , 6-month , multicenter , placebo-controlled trial evaluate combination galantamine nimodipine patient mixed dementia cognition quality life . The target dose galantamine 24 mg/day nimodipine take fixed dose 90 mg/day . Primary outcome measure computerized battery neuropsychological test Quality Life ( QoL ) score . Secondary outcome measure ADAS-cog , Clinical Global Impression ( CGI ) Neuropsychiatric Inventory ( NPI ) . Mixed dementia ( Alzheimer 's Disease ( AD ) associate cerebrovascular disease ) one common cause dementia , remain largely underdiagnosed . Little known specific treatment condition . Ischemic lesion seem play important role cognitive impairment , even presence AD pathology . Hypotheses : - Galantamine 16-24 mg/day combination nimodipine 90 mg/day superior galantamine monotherapy ( 16-24 mg/day ) improve stabilize cognition patient AD associate cerebrovascular disease ( mixed dementia ) , measure CNTB 6 month . - Galantamine 16-24 mg/day combination nimodipine 90 mg/day superior galantamine monotherapy ( 16-24 mg/day ) QoL measure population measure QoL - AD 6 month . Group 1 : galantamine oral 8mg/day month , 16mg/day 4 week 24mg/day end study plus nimodipine oral 30mg tid study . Group 2 : Group 1 : galantamine oral 8mg/day month , 16mg/day 4 week 24mg/day end study plus placebo oral 30mg tid study .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Nimodipine</mesh_term>
	<criteria>Patients fulfill DSMIV criterion dementia ( APA , 1994 ) Patients fulfill criterion AD cerebrovascular disease accord NINDSAIREN criterion ( Rom√°n et al. , 1993 ) The severity dementia mild moderate , define MMSE score 10 26 ( inclusive ) Patients ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . History neurodegenerative disorder Parkinson 's disease , Pick 's disease Huntington 's chorea , Down 's syndrome , CreutzfeldtJacob disease . Patients mild extrapyramidal sign , treatment require , excluded trial History liver renal insufficiency significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurological , psychiatric , metabolic disturbance past 6 month Patients previously receive M1 agonist cholinesterase inhibitor ( tacrine , donepezil , metrifonate , rivastigmine ) treatment Alzheimer 's disease , matter approve experimental include trial provide least washout period 60 day prior screen assessment History drug alcohol abuse within last year prior prolonged history History severe drug allergy hypersensitivity include record hypersensitivity cholinesterase inhibitor , choline agonist similar agent , bromide Subjects previously enrol galantamine trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Mixed Dementia</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Reminyl ER</keyword>
	<keyword>Nimodipine</keyword>
</DOC>